| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:3373.)
© 2002 American Heart Association, Inc.
ATP III Final Report |
References
 |
References |
|---|
 Top References |
|---|
1. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. NIH Pub. No. 93-3095. Bethesda, MD: National Heart, Lung, and Blood Institute, 1993; 180 pages.
2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation1994; 89:1333 -445.[Medline] [Order article via Infotrieve]
3. Report of the National Cholesterol Education Program Expert Panel
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:
the Expert Panel. Arch Intern Med1988; 148:36
-69.
4. National Cholesterol Education Program. High Blood Cholesterol in Adults: Report of the Expert Panel on Detection, Evaluation, and Treatment. NIH Pub. No. 88-2925. Bethesda, MD: National Heart, Lung, and Blood Institute, 1988; 87 pages.
5. National Cholesterol Education Program. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. NIH Pub. No. 90-3046. Bethesda, MD: National Heart, Lung, and Blood Institute,1990; 139 pages.
6. Report of the Expert Panel on Population Strategies for Blood
Cholesterol Reduction. A statement from the National Cholesterol Education
Program, National Heart, Lung, and Blood Institute, National Institutes of
Health. Circulation1991; 83:2154
-232.
7. Cleeman JI, Lenfant C. The National Cholesterol Education Program:
progress and prospects. JAMA1998; 280:2099
-104.
8. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol
homeostasis. Science1986; 232:34
-47.
9. Glueck CJ, Gartside PF, Fallart RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med1976; 88:941 -57.[Medline] [Order article via Infotrieve]
10. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB. Prediction of coronary heart disease using risk factor categories.
Circulation1998; 97:1837
-47.
11. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is
relationship between serum cholesterol and risk of premature death from
coronary heart disease continuous and graded? Findings in 356 222 primary
screenees of the Multiple Risk Factor Intervention Trial (MRFIT).
JAMA 1986;256:2823
-8.
12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary
Primary Prevention Trial results. I: Reduction in the incidence of coronary
heart disease. JAMA1984; 251:351
-64.
13. Lipid Research Clinics Program. The Lipid Research Clinics Coronary
Primary Prevention Trial results. II: The relationship of reduction in
incidence of coronary heart disease to cholesterol lowering.
JAMA 1984;251:365
-74.
14. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med1990; 323:1112 -9.[Medline] [Order article via Infotrieve]
15. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med1990; 322:1700 -7.[Abstract]
16. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic
factor after myocardial infarction: the Framingham Study. Ann
Intern Med 1991;115:687
-93.
17. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet1999; 353:89 -92.[CrossRef][Medline] [Order article via Infotrieve]
18. McGill HC Jr. Introduction to the geographic pathology of atherosclerosis. Lab Invest1968; 18:465 -7.[Medline] [Order article via Infotrieve]
19. Keys A, Arvanis C, Blackburn H. Seven countries: a multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press, 1980;381 .
20. Keys A, Menotti A, Aravanis C, Blackburn H, Djordjevic BS, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Kimura N, Mohacek I, Nedeljkovic S, Puddu V, Punsar S, Taylor HL, Conti S, Kromhout D, Toshima H. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med1984; 13:141 -54.[CrossRef][Medline] [Order article via Infotrieve]
21. Kagan A, Harris BR, Winkelstein W Jr, Johnson KG, Kato H, Syme SL, Rhoads GG, Gay ML, Nichaman MZ, Hamilton HB, Tillotson J. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: demographic, physical, dietary and biochemical characteristics. J Chron Dis1974; 27:345 -64.[CrossRef][Medline] [Order article via Infotrieve]
22. Toor M, Katchalsky A, Agmon J, Allalouf D. Atherosclerosis and
related factors in immigrants to Israel. Circulation1960; 22:265
-79.
23. Law MR, Wald NJ, Thompson SG. By how much and how quickly does
reduction in serum cholesterol concentration lower risk of ischaemic heart
disease? BMJ1994; 308:367
-72.
24. Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J Suppl 1999;(suppl S):S3 -S8.
25. Grundy SM, Wilhelmsen L, Rose G, Campbell RWF, Assmann G. Coronary
heart disease in high-risk populations: lessons from Finland. Eur
Heart J 1990;11:462
-71.
26. People's Republic of China-United States Cardiovascular and
Cardiopulmonary Epidemiology Research Group. An epidemiological study of
cardiovascular and cardiopulmonary disease risk factors in four populations in
the People's Republic of China: baseline report from the P.R.C.-U.S.A.
Collaborative Study. Circulation1992; 85:1083
-96.
27. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of
reducing serum cholesterol. BMJ1994; 308:373
-9.
28. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic
underestimation of association between serum cholesterol concentration and
ischaemic heart disease in observational studies: data from the BUPA study.
BMJ 1994;308:363
-6.
29. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, for the
PDAY Research Group. Effects of serum lipoproteins and smoking on
atherosclerosis in young men and women. Arterioscler Thromb Vasc
Biol 1997;17:95
-106.
30. McGill HC Jr, McMahan CA, and the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Determinants of atherosclerosis in the young. Am J Cardiol1998; 82:30T -6T.[Medline] [Order article via Infotrieve]
31. McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV,
Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP, for the
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research
Group. Associations of coronary heart disease risk factors with the
intermediate lesion of atherosclerosis in youth. Arterioscler
Thromb Vasc Biol 2000;20:1998
-2004.
32. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30
years of follow-up from the Framingham Study. JAMA1987; 257:2176
-80.
33. Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang K-Y, Levine DM.
Serum cholesterol in young men and subsequent cardiovascular disease.
N Engl J Med1993; 328:313
-8.
34. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton
JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of
younger men to long-term coronary, cardiovascular, and all-cause mortality and
to longevity. JAMA2000; 284:311
-8.
35. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull WR Jr,
Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A
definition of the intima of human arteries and of its atherosclerosisprone
regions: a report from the Committee on Vascular Lesions of the Council on
Arteriosclerosis, American Heart Association.
Circulation1992; 85:391
-405.
36. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld
ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial,
fatty streak, and intermediate lesions of atherosclerosis: a report from the
Committee on Vascular Lesions of the Council on Arteriosclerosis, American
Heart Association. Arterioscler Thromb1994; 14:840
-56.
37. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W
Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced
types of atherosclerotic lesions and a histological classification of
atherosclerosis: a report from the Committee on Vascular Lesions of the
Council on Arteriosclerosis, American Heart Association.
Circulation1995; 92:1355
-74.
38. Libby P. Molecular bases of the acute coronary syndromes.
Circulation1995; 91:2844
-50.
39. Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med1998; 104(2A):14S -8S.[Medline] [Order article via Infotrieve]
40. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet1999; 353(suppl II):SII5 -SII9.[Medline] [Order article via Infotrieve]
41. Théroux P, Fuster V. Acute coronary syndromes: unstable
angina and non-Q-wave myocardial infarction.
Circulation1998; 97:1195
-206.
42. Brown BG, Stewart BF, Zhao X-Q, Hillger LA, Poulin D, Albers JJ. What benefit can be derived from treating normocholesterolemic patients with coronary artery disease? Am J Cardiol1995; 76:93C -7C.[CrossRef][Medline] [Order article via Infotrieve]
43. Brown BG, Zhao XQ. Lipid therapy to stabilize the vulnerable atherosclerotic plaque: new insights into the prevention of cardiovascular events. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker, Inc.,2000 : 249-72.
44. Grundy SM. Cholesterol-lowering trials: a historical perspective. In: Grundy SM, ed. Cholesterol lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:1 -329.
45. Gordon DJ. Cholesterol lowering reduces mortality: the statins. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:299 -311.
46. Holmes CL, Schulzer M, Mancini GB. Angiographic results of lipid-lowering trials: a systematic review and meta-analysis. In: Grundy SM, ed. Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York: Marcel Dekker Inc., 2000:191 -220.
47. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM,
Keech A, Packard C, Simes J, Byington R, Furberg CD, for the Prospective
Pravastatin Pooling Project Investigators Group. Effect of pravastatin on
coronary disease events in subgroups defined by coronary risk factors: the
Prospective Pravastatin Pooling Project. Circulation2000; 102:1893
-900.
48. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas
FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J, for the Veterans
Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Gemfibrozil for the secondary prevention of coronary heart disease in men with
low levels of high-density lipoprotein cholesterol. N Engl J
Med 1999;341:410
-8.
49. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol1998; 81:7B -12B.[CrossRef][Medline] [Order article via Infotrieve]
50. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J1998; 19(suppl M):M8 -M14.[Medline] [Order article via Infotrieve]
51. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med1980; 302:1383 -9.[Abstract]
52. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol1998; 81:18B -25B.[CrossRef][Medline] [Order article via Infotrieve]
53. Havel RJ. Role of triglyceride-rich lipoproteins in progression of
atherosclerosis. Circulation1990; 81:694
-6.
54. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol1998; 81:13B -7B.[CrossRef][Medline] [Order article via Infotrieve]
55. Nordestgaard BG, Lewis B. Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas's Hospital rabbit strain. Atherosclerosis1991; 87:39 -46.[CrossRef][Medline] [Order article via Infotrieve]
56. Breslow JL. Mouse models of atherosclerosis. Science 1996;272:685 -8.[Abstract]
57. Weisgraber KH, Innerarity TL, Rall SC Jr, Mahley RW. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. Ann NY Acad Sci1990; 598:37 -48.[Medline] [Order article via Infotrieve]
58. Mahley RW, Weisgraber KH, Innerarity TL, Rall SC Jr. Genetic
defects in lipoprotein metabolism: elevation of atherogenic lipoproteins
caused by impaired catabolism. JAMA1991; 265:78
-83.
59. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S,
Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda
R. Intermediate-density lipoprotein and cholesterol-rich very low density
lipoprotein in angiographically determined coronary artery disease.
Circulation1981; 64:1174
-84.
60. Steiner G, Schwartz L, Shumak S, Poapst M. The association of
increased levels of intermediate-density lipoproteins with smoking and with
coronary artery disease. Circulation1987; 75:124
-30.
61. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men. Lancet 1987;2:62 -6.[CrossRef][Medline] [Order article via Infotrieve]
62. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and
progression of coronary artery disease evaluated by angiography and clinical
events. Circulation1993; 88:2762
-70.
63. Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation
of plasma levels and composition of apolipoprotein B-containing lipoproteins
to angiographically defined coronary artery disease in young patients with
myocardial infarction. Circulation1993; 88[part 1]:2180
-9.
64. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L,
Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich
lipoproteins have a differential effect on mild/moderate and severe lesion
progression as assessed by quantitative coronary angiography in a controlled
trial of lovastatin. Circulation1994; 90:42
-9.
65. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, McConathy WD, Alaupovic P. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis1996; 122:105 -15.[CrossRef][Medline] [Order article via Infotrieve]
66. Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant
lipoproteins are related to intima-media thickness of the carotid artery
independently of LDL cholesterol and plasma triglycerides. J Lipid
Res 2001;42:17
-21.
67. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis1999; 142:309 -15.[CrossRef][Medline] [Order article via Infotrieve]
68. Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J1998; 19(suppl H):H31 -H36.[Medline] [Order article via Infotrieve]
69. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ,
Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of
recurrent coronary events in the Cholesterol and Recurrent Events (CARE)
trial. Circulation2000; 102:1886
-92.
70. Kuchinskiene Z, Carlson LA. Composition, concentration, and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women. J Lipid Res1982; 23:762 -9.[Abstract]
71. Miller KW, Small DM. Surface-to-core and interparticle equilibrium
distributions of triglyceride-rich lipoprotein lipids. J Biol
Chem 1983;258:13772
-84.
72. Bjorkegren J, Boquist S, Samnegard A, Lundman P, Tornvall P,
Ericsson C-G, Hamsten A. Accumulation of apolipoprotein C-I-rich and
cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia
in normolipidemic patients with coronary artery disease.
Circulation2000; 101:227
-30.
73. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994;78:117 -41.[Medline] [Order article via Infotrieve]
74. Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am1990; 19:259 -78.[Medline] [Order article via Infotrieve]
75. Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G,
Jacobs D, Frantz ID Jr. Lipoprotein-cholesterol distributions in selected
North American populations: the Lipid Research Clinics Program Prevalence
Study. Circulation1980; 61:302
-15.
76. Denke MA, Sempos CT, Grundy SM. Excess body weight: an
underrecognized contributor to high blood cholesterol levels in white American
men. Arch Intern Med1993; 153:1093
-103.
77. Denke MA, Sempos CT, Grundy SM. Excess body weight: an
under-recognized contributor to dyslipidemia in white American women.
Arch Intern Med1994; 154:401
-10.
78. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. NIH Pub. No. 98-4083. Bethesda, MD: National Heart, Lung and Blood Institute, 1998;228 pages.
79. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obesity Res1998; 6(suppl 2):51S -209S.[Medline] [Order article via Infotrieve]
80. Hardman AE. Physical activity, obesity and blood lipids. Int J Obes Relat Metab Disord1999; 23(suppl 3):S64 -S71.
81. Berg A, Halle M, Franz I, Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials. Eur J Med Res 1997;2:259 -64.[Medline] [Order article via Infotrieve]
82. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest1973; 52:1544 -68.[Medline] [Order article via Infotrieve]
83. Havel RJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol2000; 11:615 -20.[CrossRef][Medline] [Order article via Infotrieve]
84. Wilson MA, Vega GL, Gylling H, Grundy SM. Persistence of
abnormalities in metabolism of apolipoproteins B-100 and A-I after weight
reduction in patients with primary hypertriglyceridemia.
Arteriosclerosis Thrombosis1992; 12:976
-84.
85. Vega GL, Grundy SM. Gemfibrozil therapy in primary
hypertriglyceridemia associated with coronary heart disease.
JAMA 1985;253:2398
-403.
86. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with
lovastatin. Arch Intern Med1990; 150:1313
-9.
87. Vega GL, Grundy SM. Lipoprotein responses to treatment with
lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with
hypoalphalipoproteinemia. Arch Intern Med1994; 154:73
-82.
88. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol1997; 79:1298 -301.[CrossRef][Medline] [Order article via Infotrieve]
89. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors
of the severity of coronary artery disease in men and women.
Circulation1985; 71:881
-8.
90. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP,
Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein
cholesterol and cardiovascular disease: four prospective American studies.
Circulation1989; 79:8
-15.
91. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol1998; 81:26B -31B.[CrossRef][Medline] [Order article via Infotrieve]
92. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik
PS, Bush TL. Non-high-density lipoprotein cholesterol level as a predictor of
cardiovascular disease mortality. Arch Intern Med2001; 161:1413
-9.
93. Vega GL, Grundy SM. Does measurement of apolipoprotein B have a
place in cholesterol management[Editorial]?
Arteriosclerosis1990; 10:668
-71.
94. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis1993; 104:159 -71.[CrossRef][Medline] [Order article via Infotrieve]
95. Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G.
Plasma apoproteins and the severity of coronary artery disease.
Circulation1986; 73:978
-86.
96. Sniderman AD. Apolipoprotein B and apolipoprotein AI as predictors of coronary artery disease. Can J Cardiol1988; 4(suppl A):24A -30A.[Medline] [Order article via Infotrieve]
97. Marcovina S, Zoppo A, Graziani MS, Vassanelli C, Catapano AL. Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease. La Ric Clin Lab1988; 18:319 -28.[CrossRef][Medline] [Order article via Infotrieve]
98. Reinhart RA, Gani K, Arndt MR, Broste SK. Apolipoproteins A-I and B
as predictors of angiographically defined coronary artery disease.
Arch Intern Med1990; 150:1629
-33.
99. Sniderman A, Vu H, Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis1991; 89:109 -16.[CrossRef][Medline] [Order article via Infotrieve]
100. Levinson SS, Wagner SG. Measurement of apolipoprotein B-containing lipoproteins for routine clinical laboratory use in cardiovascular disease. Arch Pathol Lab Med1992; 116:1350 -4.[Medline] [Order article via Infotrieve]
101. Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol1992; 69:1015 -21.[CrossRef][Medline] [Order article via Infotrieve]
102. Westerveld HT, Roeters van Lennep JE, Roeters van Lennep HW, Liem
A-H, de Boo JA, van der Schouw YT, Erkelens W. Apolipoprotein B and coronary
artery disease in women: a cross-sectional study in women undergoing their
first coronary angiography. Arterioscler Thromb Vasc
Biol 1998;18:1101
-7.
103. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S,
Jou JY, Langendörfer A, Beere PA, Watson DJ, Downs JR, de Cani JS.
Relation between baseline and on-treatment lipid parameters and first acute
major coronary events in the Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS). Circulation2000; 101:477
-84.
104. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard P-M, Dagenais
GR, Despres J-P. Apolipoprotein A-I and B levels and the risk of ischemic
heart disease during a five-year follow-up of men in the Quebec Cardiovascular
Study. Circulation1996; 94:273
-8.
105. Lemieux I, Pascot A, Couillard C, Lamarche B, T chernof A, Almeras
N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Despres J-P.
Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad
(hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?
Circulation2000; 102:179
-84.
106. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid
distributions in selected North American populations: the Lipid Research
Clinics Program Prevalence Study. Circulation1979; 60:427
-39.
107. Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes
on survival following myocardial infarction in men vs women: the Framingham
Study. JAMA1988; 260:3456
-60.
108. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol1980; 46:649 -54.[CrossRef][Medline] [Order article via Infotrieve]
109. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis1996; 124(suppl 6):S11 -S20.[CrossRef][Medline] [Order article via Infotrieve]
110. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature1991; 353:265 -7.[CrossRef][Medline] [Order article via Infotrieve]
111. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene
expression increases high density lipoprotein and suppresses atherosclerosis
in apolipoprotein E-deficient mouse. Proc Natl Acad Sci
USA 1994;91:9607
-11.
112. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Puré E, Rader
DJ. Regression of atherosclerosis induced by liver-directed gene transfer of
apolipoprotein A-I in mice. Circulation1999; 100:1816
-22.
113. Tall AR. An overview of reverse cholesterol transport. Eur Heart J1998; 19(suppl A):A31 -A35.[Medline] [Order article via Infotrieve]
114. van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758 -67.[Medline] [Order article via Infotrieve]
115. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD,
Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein
inhibits three steps in the formation of mildly oxidized low density
lipoprotein: steps 2 and 3. J Lipid Res2000; 41:1495
-508.
116. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L,
Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high
density lipoprotein inhibits three steps in the formation of mildly oxidized
low density lipoprotein: step 1. J Lipid Res2000; 41:1481
-94.
117. Ng DS, Vezina C, Wolever TS, Kuksis A, Hegele RA, Connelly PW.
Apolipoprotein A-I deficiency: biochemical and metabolic characteristics.
Arterioscler Thromb Vasc Biol1995; 15:2157
-64.
118. Miller M, Aiello D, Pritchard H, Friel G, Zeller K. Apolipoprotein
A-I Zavalla (Leu159
Pro): HDL cholesterol
deficiency in a kindred associated with premature coronary artery disease.
Arterioscler Thromb Vasc Biol1998; 18:1242
-7.
119. Römling R, von Eckardstein A, Funke H, Motti C, Fragiacomo GC,
Noseda G, Assmann G. A nonsense mutation in the apolipoprotein A-I gene is
associated with high-density lipoprotein deficiency and periorbital
xanthelasmas. Arterioscler Thromb1994; 14:1915
-22.
120. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H,
Kajiyama G, Arakawa K. A new case of Apo A-I deficiency showing codon 8
nonsense mutation of the Apo A-I gene without evidence of coronary heart
disease. Arterioscler Thromb Vasc Biol1995; 15:1866
-74.
121. Miccoli R, Bertolotto A, Navalesi R, Odoguardi L, Boni A, Wessling
J, Funke H, Wiebusch H, von Eckardstein A, Assmann G. Compound heterozygosity
for a structural apolipoprotein A-I variant, apo A-I (L141R) Pisa,
and an apolipoprotein A-I null allele in patients with absence of HDL
cholesterol, corneal opacifications, and coronary heart disease.
Circulation1996; 94:1622
-8.
122. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996;7:209 -16.[Medline] [Order article via Infotrieve]
123. Schaefer EJ, Lamon-Fava S, Ordovas JM, Cohn SD, Schaefer MM, Castelli WP, Wilson PWF. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res1994; 35:871 -82.[Abstract]
124. Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of
serum and lipoprotein cholesterol and triglycerides: association with
adiposity and the consumption of ethanol, tobacco, and beverages containing
caffeine. Arteriosclerosis1981; 1:13
-24.
125. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic
lipoprotein phenotype: a proposed genetic marker for coronary heart disease
risk. Circulation1990; 82:495
-506.
126. Luc G, Bard JM, Poulain P, Arveiler D, Evans AE, Cambien F, Fruchart JC, Ducimetiere P. Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM Study. Eur J Clin Invest 1997;27:242 -7.[CrossRef][Medline] [Order article via Infotrieve]
127. Rainwater DL. Lipoprotein correlates of LDL particle size. Atherosclerosis2000; 148:151 -8.[CrossRef][Medline] [Order article via Infotrieve]
128. Austin MA, Rodriguez BL, McKnight B, McNeely MJ, Edwards KL, Curb JD, Sharp DS. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol2000; 86:412 -6.[CrossRef][Medline] [Order article via Infotrieve]
129. Krauss RM. Regulation of high density lipoprotein levels. Med Clin North Am1982; 66:403 -30.[Medline] [Order article via Infotrieve]
130. Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest1994; 94:2377 -84.[Medline] [Order article via Infotrieve]
131. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res2000; 8:605 -19.[Medline] [Order article via Infotrieve]
132. Nie L, Wang J, Clark LT, Tang A, Vega GL, Grundy SM, Cohen JC. Body
mass index and hepatic lipase gene (LIPC) polymorphism jointly influence
postheparin plasma hepatic lipase activity. J Lipid
Res 1998;39:1127
-30.
133. Carr MC, Hokanson JE, Deeb SS, Purnell JQ, Mitchell ES, Brunzell
JD. A hepatic lipase gene promoter polymorphism attenuates the increase in
hepatic lipase activity with increasing intra-abdominal fat in women.
Arterioscler Thromb Vasc Biol1999; 19:2701
-7.
134. Tato F, Vega GL, Grundy SM. Bimodal distribution of cholesteryl
ester transfer protein activities in normotriglyceridemic men with low HDL
cholesterol concentrations. Arterioscler Thromb Vasc
Biol 1995;15:446
-51.
135. Karhapää P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin-resistant state. Diabetes1994; 43:411 -7.[Abstract]
136. Lamarche B, Despres J-P, Pouliot M-C, Prud'homme D, Moorjani S,
Lupien PJ, Nadeau A, Tremblay A, Bouchard C. Metabolic heterogeneity
associated with high plasma triglyceride or low HDL cholesterol levels in men.
Arterioscler Thromb1993; 13:33
-40.
137. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol1992; 70:733 -7.[CrossRef][Medline] [Order article via Infotrieve]
138. Martin-Jadraque R, Tato F, Mostaza JM, Vega GL, Grundy SM.
Effectiveness of low-dose crystalline nicotinic acid in men with low
high-density lipoprotein cholesterol levels. Arch Intern
Med 1996;156:1081
-8.
139. Frick MH, Elo MO, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987; 317:1237 -45.[Abstract]
140. Kastelein JJP, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, Davidson MH, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB for the Simvastatin Atorvastatin HDL Study Group. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000;86:221 -3.[CrossRef][Medline] [Order article via Infotrieve]
141. Coronary Drug Project Research Group. Clofibrate and niacin in
coronary heart disease. JAMA1975; 231:360
-81.
142. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss
RM. Low-density lipoprotein subclass patterns and risk of myocardial
infarction. JAMA1988; 260:1917
-21.
143. Verges BL. Dyslipidaemia in diabetes mellitus: review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab1999; 25(suppl 3):32 -40.[Medline] [Order article via Infotrieve]
144. Durrington PN. Diabetic dyslipidaemia. Baillière's Clin Endocrinol Metab1999; 13:265 -78.[CrossRef][Medline] [Order article via Infotrieve]
145. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82:67U -73U.[CrossRef][Medline] [Order article via Infotrieve]
146. Kokkinos PF, Fernhall B. Physical activity and high density lipoprotein cholesterol levels: what is the relationship? Sports Med 1999;28:307 -14.[CrossRef][Medline] [Order article via Infotrieve]
147. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM,
Nash DT, Nash SD, for the Niaspan-Gemfibrozil Study Group. Extended-release
niacin vs. gemfibrozil for the treatment of low levels of high-density
lipoprotein cholesterol. Arch Intern Med2000; 160:1177
-84.
148. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in
patients with isolated hypoalphalipoproteinemia: a randomized, open-label,
crossover study. J Am Coll Cardiol2000; 35:640
-6.
149. Committee of Principal Investigators. A co-operative trial in the
primary prevention of ischemic heart disease using clofibrate: Report from the
Committee of Principal Investigators. Br Heart J1978; 40:1069
-118.
150. Group of Physicians of the Newcastle upon Tyne Region. Trial of
clofibrate in the treatment of ischaemic heart disease: five year study by a
group of physicians of the New Castle upon Tyne region.
BMJ 1971;4:767
-75.
151. Research Committee of the Scottish Society of Physicians. Ischaemic
heart disease: a secondary prevention trial using clofibrate.
BMJ 1971;4:775
-84.
152. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand1988; 223:405 -18.[Medline] [Order article via Infotrieve]
153. Bezafibrate Infarction Prevention (BIP) Study Group. Secondary
prevention by raising HDL cholesterol and reducing triglycerides in patients
with coronary artery disease. Circulation2000; 102:21
-7.
154. Ericsson C-G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849 -53.[CrossRef][Medline] [Order article via Infotrieve]
155. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S,
Virtanen V, Kesäniemi YA, Pasternack A, Taskinen M-R, for the Lopid
Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic
progression of coronary and vein-graft atherosclerosis by gemfibrozil after
coronary bypass surgery in men with low levels of HDL cholesterol.
Circulation1997; 96:2137
-43.
156. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357:905 -10.[CrossRef][Medline] [Order article via Infotrieve]
157. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP,
Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on
coronary atherosclerosis and coronary venous bypass grafts.
JAMA 1987;257:3233
-40.
158. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med1990; 323:1289 -98.[Abstract]
159. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy
AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and
niacin, antioxidant vitamins, or the combination for the prevention of
coronary disease. N Engl J Med2001; 345:1583
-92.
160. JNC VI. The sixth report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med1997; 157:2413
-46.
161. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth Report. NIH Pub. No. 98-4080. Bethesda, MD: Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute,1997; 70.
162. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease: part 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765 -74.[CrossRef][Medline] [Order article via Infotrieve]
163. Selmer R. Blood pressure and twenty-year mortality in the city of
Bergen, Norway. Am J Epidemiol1992; 136:428
-40.
164. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and
diastolic, and cardiovascular risks: U.S. population data. Arch
Intern Med 1993;153:598
-615.
165. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older persons with isolated systolic hypertension. Lancet 1997;1:757 -64.
166. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure
useful in predicting risk for coronary heart disease? The Framingham Heart
Study. Circulation1999; 100:354
-60.
167. van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A,
Nissinen A, Kromhout D, for the Seven Countries Research Group. The relation
between blood pressure and mortality due to coronary heart disease among men
in different parts of the world. N Engl J Med2000; 342:1
-8.
168. Rodgers A, MacMahon S. Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens1999; 21:543 -52.[CrossRef][Medline] [Order article via Infotrieve]
169. Vasan RS, Larson MG, Evans JC, O'Donnell CJ, Levy D. High normal blood pressure and risk of cardiovascular disease: the Framingham Heart Study. Circulation1999; 100(18 suppl 1):34 .
170. Cutler JA, Psaty BM, MacMahon S, Furberg CD. Public health issues in hypertension control: what has been learned from clinical trials. In: Laragh JH, Brenner BM eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press, 1995:253 -70.
171. SHEP Cooperative Research Group. Prevention of stroke by
antihypertensive drug treatment in older persons with isolated systolic
hypertension: final results of the Systolic Hypertension in the Elderly
Program (SHEP). JAMA1991; 265:3255
-64.
172. Working Group Report on Management of Patients with Hypertension and High Blood Cholesterol. NIH Pub. No. 90-2361. Bethesda, MD: National Heart, Lung, and Blood Institute, 1990;30 pages.
173. Working Group on Management of Patients with Hypertension and High
Blood Cholesterol. National Education Programs Working Group Report on the
Management of Hypertension and High Blood Cholesterol. Ann Intern
Med 1991;114:224
-37.
174. Meigs JB, D'Agostino RB Sr, Wilson PWF, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes1997; 46:1594 -600.[Abstract]
175. Doll R, Peto R. Mortality in relation to smoking: 20 years'
observations on male British doctors. BMJ1976; 2:1525
-36.
176. Doll R, Gray R, Hafner B, Peto R. Mortality in relation to smoking:
22 years' observations on female British doctors. BMJ1980; 280:967
-71.
177. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO, for the MRFIT Research Group. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J1986; 112:825 -36.[CrossRef][Medline] [Order article via Infotrieve]
178. Colditz GA, Bonita R, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med1988; 318:937 -41.[Abstract]
179. Wolf PA, D'Agostino RB, Kannel WB, Bonita R, Belanger AJ. Cigarette
smoking as a risk factor for stroke: the Framingham Study.
JAMA 1988;259:1025
-9.
180. U.S. Department of Health and Human Services. Reducing the health consequences of smoking: 25 years of progress. A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS pub. No. (CDC) 89-8411. Bethesda, MD: 1989; 703 pages.
181. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303 -9.[Abstract]
182. LaCroix AZ, Lang J, Scherr P, Wallace RB, Cornoni-Huntley J, Berkman L, Curb JB, Evans D, Hennekens CH. Smoking and mortality among older men and women in three communities. N Engl J Med1991; 324:1619 -25.[Abstract]
183. McBride PE. The health consequences of smoking; cardiovascular diseases. Med Clin North Am1992; 76:333 -53.[Medline] [Order article via Infotrieve]
184. Jonas MA, Oates JA, Ockene JK, Hennekens CH. Statement on smoking
and cardiovascular disease for health care professionals.
Circulation1992; 86:1664
-9.
185. Pyörälä K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis1994; 110:121 -61.[CrossRef][Medline] [Order article via Infotrieve]
186. U.S. Department of Health and Human Services. The health benefits of smoking cessation. A Report of the Surgeon General. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. DHHS pub. No. (CDC) 90-8416, Washington, D.C.: U.S. Department of Health and Human Services, 1990.627 pages.
187. Hjermann I, Holme I, Velve BK, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981;2:1303 -10.[CrossRef][Medline] [Order article via Infotrieve]
188. Rose G, Hamilton PJS, Colwell L, Shipley MJ. A randomised
controlled trial of anti-smoking advice: 10-year results. J
Epidemiol Community Health1982; 36:102
-8.
189. Multiple Risk Factor Intervention Trial Research Group. Multiple
Risk Factor Intervention Trial: risk factor changes and mortality results.
JAMA 1982;248:1465
-77.
190. Gavin JR III, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, Genuth S, Harris MI, Kahn R, Keen H, Knowler WC, Lebovitz H, Maclaren NK, Palmer JP, Raksin P, Rizza RA, Stern MP. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care1998; 21(suppl):S5 -S19.[CrossRef]
191. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the
Framingham Study. JAMA1979; 241:2035
-8.
192. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979;2:120 -6.[Abstract]
193. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, and Bennett PH eds.Diabetes in America , 2nd edition. Bethesda, MD: U.S. Department of Health and Human Services, 1995:429 -48.
194. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463 -524.[Medline] [Order article via Infotrieve]
195. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in
diabetes. Arterioscler Thromb1992; 12:647
-56.
196. Herlitz J, Karlson BW, Edrardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology1992; 80:237 -45.[Medline] [Order article via Infotrieve]
197. Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner SM, Pyörälä K, Tuomilehto J, for the FINMONICA Myocardial Infarction Register Study group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care1998; 21:69 -75.[Abstract]
198. Diabetes Control and Complications Trial Research Group. The effect
of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N
Engl J Med 1993;329:977
-86.
199. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998; 352:854 -65.[CrossRef][Medline] [Order article via Infotrieve]
200. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352:837 -53.[CrossRef][Medline] [Order article via Infotrieve]
201. UK Prospective Diabetes Study Group. Efficacy of atenolol and
captopril in reducing risk of macrovascular and microvascular complications in
type 2 diabetes: UKPDS 39. BMJ1998; 317:713
-20.
202. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2 diabetes:
UKPDS 38. BMJ1998; 317:703
-13.
203. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997; 20:614 -20.[Abstract]
204. Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA,
Pedersen TR, Kjekshus J, Pyörälä K, for the Scandinavian
Simvastatin Survival Study Group. Reduced coronary events in
simvastatin-treated patients with coronary heart disease and diabetes or
impaired fasting glucose levels: subgroup analyses from the Scandinavian
Simvastatin Survival Study. Arch Intern Med1999; 159:2661
-7.
205. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV,
Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E, for the CARE
Investigators. Cardiovascular events and their reduction with pravastatin in
diabetic and glucose-intolerant myocardial infarction survivors with average
cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events
(CARE) trial. Circulation1998; 98:2513
-9.
206. Long-Term Intervention with Pravastatin in Ischaemic Disease
(LIPID) Study Group. Prevention of cardiovascular events and death with
pravastatin in patients with coronary heart disease and a broad range of
initial cholesterol levels. N Engl J Med1998; 339:1349
-57.
207. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA,
Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/TexCAPS
Research Group. Primary prevention of acute coronary events with lovastatin in
men and women with average cholesterol levels: results of AFCAPS/TexCAPS.
JAMA 1998;279:1615
-22.
208. Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, Geller N, Herd A, Hickey A, Hunninghake DB, Knatterud GL, White C. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft trial. Diabetes1999; 48:1289 -94.[Abstract]
209. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992; 15:820 -5.[Abstract]
210. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K,
Laakso M. Mortality from coronary heart disease in subjects with type 2
diabetes and in nondiabetic subjects with and without prior myocardial
infarction. N Engl J Med1998; 339:229
-34.
211. Haffner SM, D'Agostino RD Jr, Saad MF, O'Leary DH, Savage PJ, Rewers M, Selby J, Bergman RN, Mykkänen L. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease: the Insulin Resistance Atherosclerosis Study. Am J Cardiol2000; 85:1395 -400.[CrossRef][Medline] [Order article via Infotrieve]
212. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas
L, Calvin J, Keltai M, Budaj A, for the OASIS Registry Investigators. Impact
of diabetes on long-term prognosis in patients with unstable angina and
non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess
Strategies for Ischemic Syndromes) Registry.
Circulation2000; 102:1014
-9.
213. Hu FB, Stampfer MJ, Solomon C, Willett WC, Manson JE. Diabetes mellitus and mortality from all causes and coronary heart disease in women: 20 years of follow-up. Diabetes2000; 49(suppl 1):A20 .[CrossRef]
214. Simons LA, Simons J. Diabetes and coronary heart disease [Letter].
N Engl J Med1998; 339:1714
-5.
215. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an
independent risk factor for cardiovascular disease: a 26-year follow-up of
participants in the Framingham Heart Study.
Circulation1983; 67:968
-77.
216. Wilcosky T, Hyde J, Anderson JJB, Bangdiwala S, Duncan B. Obesity and mortality in the Lipid Research Clinics Program Follow-Up Study. J Clin Epidemiol1990; 43:743 -52.[CrossRef][Medline] [Order article via Infotrieve]
217. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med1990; 322:882 -9.[Abstract]
218. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass
index and mortality in a prospective cohort of U.S. adults. N Engl
J Med 1999;341:1097
-105.
219. Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity: studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest1974; 53:64 -76.[Medline] [Order article via Infotrieve]
220. Grundy SM, Mok HYI, Zech L, Steinberg D, Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest1979; 63:1274 -83.[CrossRef][Medline] [Order article via Infotrieve]
221. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham Offspring Study. Metabolism1980; 29:1053 -60.[CrossRef][Medline] [Order article via Infotrieve]
222. Hartz AJ, Rupley DC, Kalkhoff RD, Rimm AA. Relationship of obesity to diabetes: influence of obesity level and body fat distribution. Prev Med 1983;12:351 -7.[CrossRef][Medline] [Order article via Infotrieve]
223. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as
risk factors for diabetes and cardiovascular disease.
Arteriosclerosis1986; 6:123
-30.
224. Berchtold P, Berger M, Jorgens V, Daweke C, Chantelau E, Gries FA, Zimmermann H. Cardiovascular risk factors and HDL-cholesterol levels in obesity. Int J Obes1981; 5:1 -10.[Medline] [Order article via Infotrieve]
225. Berchtold P, Jorgens V, Finke C, Berger M. Epidemiology of ob